RECRUITING

CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study

Talk to us

Conditions

Healthy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate pulmonary capillary wedge pressure (PCWP) and other hemodynamic measurements at rest and during exercise in healthy volunteers across the age spectrum.

Official Title

CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study

Quick Facts

Study Start:2024-12-01
Study Completion:2029-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06220396

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Apparently healthy volunteers are eligible to participate in this study if they are free of symptoms of exertional breathlessness or fatigue and any diagnosis of heart failure.
  2. * Patients will also be required to have left ventricular ejection fraction (EF) ≥ 50%.
  3. * Patients discovered to reduced EF or abnormal resting hemodynamics or other pathologic findings previously undiscovered will be considered screen failures and can be replaced by others to reach the goal enrollment.
  4. * Informed consent were obtained.
  5. * No history of heart failure.
  6. * Willing and able to undergo invasive hemodynamic exercise testing, MRI, and other study assessments.
  1. * Clinically significant symptoms of exertional dyspnea or fatigue in daily life in the opinion of the investigators.
  2. * Any diagnosis of heart failure
  3. * Symptomatic coronary artery disease (e.g., patients with chronic angina)
  4. * Symptomatic valvular heart disease
  5. * Pulmonary hypertension
  6. * Cardiomyopathies
  7. * High output heart failure
  8. * Pericardial disease
  9. * Clinically significant chronic lung disease in the opinion of the investigators
  10. * Anemia (hemoglobin \<12 gm/dL in women and \<13 gm/dL in men)
  11. * Estimated glomerular filtration rate ≤30mL/min
  12. * Pregnant women
  13. * Any other disorders or problems that would interfere with the ability to participate safely in the study (e.g. psychiatric disorder or substance abuse)

Contacts and Locations

Study Contact

Dr. Borluag's Research Team
CONTACT
507-255-2200
Barry Borlaug, MD
CONTACT
(507) 255-1051
Borlaug.Barry@mayo.edu

Principal Investigator

Barry Borlaug, MD
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Barry Borlaug, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-01
Study Completion Date2029-01

Study Record Updates

Study Start Date2024-12-01
Study Completion Date2029-01

Terms related to this study

Additional Relevant MeSH Terms

  • Healthy